

Upneeq (oxymetazoline ophthalmic solution)

Override(s)	Approval Duration
Prior Authorization	Initial Approval Duration: 3 months
Quantity Limit	Continuation Approval Duration: 1 year

Medications	Quantity Limit
Upneeq (oxymetazoline ophthalmic solution)	May be subject to quantity limit

APPROVAL CRITERIA

Initial requests for Upneeq (oxymetazoline ophthalmic solution) may be approved if the following criteria are met:

- I. Individual has a diagnosis of acquired blepharoptosis; **AND**
- II. Documentation is provided that individual has a loss of visual field confirmed by (NCT 02436759):
 - A. Loss of 8 or more points on the top two rows of a Leicester Peripheral Field Test (LPFT); **AND**
 - B. Marginal reflex distance 1 (MRD1; the distance from the central pupillary light reflex to the central margin of the upper lid) of less than or equal to 2 mm.

Continuation requests for Upneeq (oxymetazoline ophthalmic solution) may be approved if the following criterion is met (NCT 02436759, NCT 03565887):

- I. Documentation is provided of clinically significant improvement in visual field on the Leicester Peripheral Field Test (LPFT) or on marginal reflex distance 1 (MRD1).

Upneeq (oxymetazoline ophthalmic solution) may not be approved for the following (NCT 02436759, NCT 03565887):

- I. Blepharoptosis that is cosmetic and does not impair the visual field; **OR**
- II. Congenital blepharoptosis; **OR**
- III. Horner syndrome; **OR**
- IV. Myasthenia gravis; **OR**
- V. Mechanical blepharoptosis (including blepharoptosis due to orbital or lid tumor).

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: August 29, 2022.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

3. Ho SF, Morawski A, Sampath R, et. al. Modified visual field test for ptosis surgery (Leicester Peripheral Field Test). *Eye (Lond)*. 2011;25(3):365-369.
4. Lee MS. Overview of ptosis. Last updated: March 17, 2021. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: September 3, 2022.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
6. RVL Pharmaceuticals, Inc. Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis. NLM Identifier: NCT 03565887. Last updated: September 16, 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT03565887?term=RVL1201&draw=2&rank=3>. Accessed: September 3, 2022.
7. RVL Pharmaceuticals, Inc. Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis. NLM Identifier: NCT 02436759. Last updated: October 20, 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT02436759?term=RVL1201&draw=2&rank=2>. Accessed: September 3, 2022.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.